World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
71
Citations
27708
World Ranking
19934
National Ranking
58

Alberto Gabizon publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alberto Gabizon sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 176 publications — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alberto Gabizon D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alberto Gabizon sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 71 D-Index — 1st percentile

1% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alberto Gabizon is affiliated with Shaare Zedek Medical Center in Israel. Their research spans multiple disciplines including medicine, materials science, and engineering, with a particular focus on biomedical engineering and biomaterials. Their work intersects oncology, molecular biology, and surgery, reflecting a broad engagement with both fundamental and applied aspects of medical science.

The scientist has contributed extensively to topics such as nanoparticle-based drug delivery and nanoplatforms for cancer theranostics. Other research interests include RNA interference and gene delivery, cancer immunotherapy and biomarkers, cancer treatment and pharmacology, graphene and nanomaterials applications, alongside general cancer research and treatments.

Frequent coauthors in their publications include Hilary Shmeeda, Ninh M. La-Beck, Yasmine Amitay, Patricia Ohana, and Jalpa Patel, indicating collaborative work within a network of experts in related fields.

Alberto Gabizon has published numerous papers, with notable recent works including:

  • "Complement Activation: A Potential Threat on the Safety of Poly(ethylene glycol)-Coated Nanomedicines" (2020, ACS Nano)
  • "Translational considerations in nanomedicine: The oncology perspective" (2020, Advanced Drug Delivery Reviews)
  • "Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective" (2025, BMJ Oncology)
  • "Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions" (2024, ACS Nano)
  • "Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside" (2020, Advanced Drug Delivery Reviews)

The scientist's publications frequently appear in high-impact venues, including ACS Nano, Advanced Drug Delivery Reviews, Journal of Controlled Release, Pharmaceutics, and Cancer Immunology Research. This reflects the interdisciplinary nature and application breadth of their work.

Best Publications

  • Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

    Alberto Gabizon;Hilary Shmeeda;Yechezkel Barenholz

  • Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

    D Papahadjopoulos;T M Allen;A Gabizon;E Mayhew

  • Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

    Alberto Gabizon;Raphael Catane;Beatrice Uziely;Bela Kaufman

  • Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

    Alberto Gabizon;Demetrios Papahadjopoulos

  • Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology

    Uma Prabhakar;Hiroshi Maeda;Rakesh K. Jain;Eva M. Sevick-Muraca

  • Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times

    D.D. Lasic;F.J. Martin;A. Gabizon;S.K. Huang

  • Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

    T. Safra;F. Muggia;S. Jeffers;D. D. Tsao-Wei

  • Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.

    Alberto A. Gabizon

  • Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates.

    Alberto Gabizon;Hilary Shmeeda;Hilary Shmeeda;Aviva T Horowitz;Aviva T Horowitz;Samuel Zalipsky;Samuel Zalipsky

  • Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes

    Alberto A. Gabizon

  • Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

    Beatrice Uziely;Susan Jeffers;Rut Isacson;Kimberlea Kutsch

  • Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

    Dorit Goren;Aviva T. Horowitz;Dina Tzemach;Mark Tarshish

  • Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

    Janos Szebeni;Franco Muggia;Alberto Gabizon;Yechezkel Barenholz

  • Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.

    Olga Lyass;Beatrice Uziely;Rami Ben-Yosef;Dinah Tzemach

  • Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

    A Gabizon;A Dagan;D Goren;Y Barenholz

  • In Vivo Fate of Folate-Targeted Polyethylene-Glycol Liposomes in Tumor-Bearing Mice

    Alberto Gabizon;Aviva T. Horowitz;Dorit Goren;Dina Tzemach

  • Pros and Cons of the Liposome Platform in Cancer Drug Targeting

    Alberto A Gabizon;Hilary Shmeeda;Samuel Zalipsky

  • Pharmacokinetics and Tissue Distribution of Doxorubicin Encapsulated in Stable Liposomes With Long Circulation Times

    Alberto Gabizon;Renee Shiota;Demetrios Papahadjopoulos

  • Ultrasound triggered release of cisplatin from liposomes in murine tumors.

    Avi Schroeder;Reuma Honen;Keren Turjeman;Alberto Gabizon

  • Liposome circulation time and tumor targeting: implications for cancer chemotherapy

    Alberto A. Gabizon

Frequent Co-Authors

Yechezkel Barenholz
Yechezkel Barenholz Hebrew University of Jerusalem
John Maher
John Maher King's College London
Franco M. Muggia
Franco M. Muggia New York University
Demetrios Papahadjopoulos
Demetrios Papahadjopoulos University of California, San Francisco
Philip J. Blower
Philip J. Blower King's College London
Theresa M. Allen
Theresa M. Allen University of Alberta
Piotr Grodzinski
Piotr Grodzinski National Institutes of Health
Zvi Fuks
Zvi Fuks Memorial Sloan Kettering Cancer Center
Paolo Caliceti
Paolo Caliceti University of Padua
Janos Szebeni
Janos Szebeni Semmelweis University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA is a popular option, there are many related online degrees that can open doors to rewarding healthcare careers. For those interested in healthcare leadership and management, a health administration degree online provides essential skills in policy, finance, and operations.

If you're aiming for advanced roles, exploring the cheapest mha online programs can help you further specialize in healthcare administration while keeping costs affordable.

Expanding your clinical expertise? The best online bsn to dnp programs let registered nurses seamlessly earn a doctoral degree, preparing them for leadership, research, or academic roles.

Likewise, pharmacists can advance their education conveniently through online pharmd programs, gaining in-depth clinical and pharmaceutical knowledge.

These flexible online pathways offer accessible, affordable, and specialized career options for those drawn to the healthcare field, beyond the traditional route of earning a medical degree.

Best Scientists Citing Alberto Gabizon

Trending Scientists

Recently Published Articles